Turnstone Biologics develops patent portfolios for its oncolytic virus clinical candidate

Client(s) Turnstone Biologics Corp.

Jones Day is representing Turnstone Biologics Corp. in the development of patent portfolios covering its oncolytic virus programs. Turnstone is a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor infiltrating lymphocytes (TIL) therapy, which may be employed alone or, e.g., in conjunction with oncolytic virus therapies.